Due to the facts that (i) the impact of single nucleotide polymorphisms and alternative splicing of ASM with respect to susceptibility and progression of infection is not fully understood and (ii) pharmacological inhibition of the enzyme resulted in improved outcome from chronic infection, the role of ASM should not be evaluated as exclusively favorable without any restriction. This evidence concerns the gene H19 and infection.